The daily use of specific
antiretroviral medications by persons without HIV infection, but at
high risk of sexual or injection exposure to HIV, has been shown to
be a safe and effective HIV prevention method. The FDA approved the
use of Truvada® for preexposure prophylaxis (PrEP) in July 2012 and
Public Health Services (PHS) has issued clinical practice
guidelines for its use. CDC requests approval to collect data over
3 years that will be used to conduct research with 175 clinicians
about their knowledge, attitudes, and practices related to a new
intervention (PrEP) over the period of its initial introduction in
their clinics. The knowledge gained will be used to refine
measurement instruments and methods, develop training and
educational resources and tools for use by CDC/Division of HIV/AIDS
Prevention-funded partners, and other organizations supporting
delivery of PrEP in clinical settings. The results may be shared at
scientific meetings, distribution to technical assistance providers
for clinical HIV prevention partners, and publication of a
report.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.